{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:02Z","timestamp":1792812662463,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Body composition analysis, particularly the assessment of sarcopenia and myosteatosis, has emerged as a potential prognostic tool in oncology. However, the clinical implication of body composition parameters remains inconsistent, largely due to the variability in cutoff values used across studies. This study examines the influence on prevalence and prognostic influence of different cutoff values for sarcopenia and myosteatosis in patients in a standardized cohort from a large clinical trial (SORAMIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 179 patients with unresectable liver cancer from the palliative arm of the SORAMIC trial. Skeletal muscle index (SMI) was calculated by measuring the cross-sectional area of skeletal muscle at the third lumbar vertebra (L3) on baseline CT scans. We then applied 14 published cutoff definitions for sarcopenia (SMI) and 7 for myosteatosis (muscle attenuation) to determine their prevalence in this cohort. Cox regression models were used to analyze the relationship between sarcopenia, myosteatosis, and OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of sarcopenia ranged from 8.9% (Van der Werf et al.) to 69.8% (Lanic et al.). Overall, 3 of the 14 cutoffs [Van Vledder et al. (HR =\u00a01.53, p\u00a0= 0.03), Coelen et al. (HR =\u00a01.46, p\u00a0= 0.03), and Derstine et al. (HR =\u00a01.47, p\u00a0= 0.04)] showed a relevant association with OS. Other cut off values were not associated with OS.<\/jats:p>\n                    <jats:p>The prevalence of myosteatosis varied between 10.1% (Nachit et al.) and 53.1% (Zhang et al.). One of the 7 cutoffs (Chu et al.) demonstrated a relevant association with OS (HR =\u00a01.53, p\u00a0= 0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The large variability in prevalence and prognostic impact observed across different cutoff definitions underscores the urgent need for standardized, cancer-specific cutoff values for SMI and muscle attenuation. Establishing uniform criteria will enhance the reliability and clinical applicability of body composition metrics as prognostic tools in oncology. Further research should focus on refining these cutoffs and validating them across diverse cancer populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06190-1","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:26:19Z","timestamp":1744813579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Different cutoff values of the skeletal muscle mass and myosteatosis result in different clinical impact on overall survival in oncology. A subanalysis of a clinical trial"],"prefix":"10.1007","volume":"151","author":[{"given":"Alexey","family":"Surov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Thormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wienke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"6190_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102839","volume":"145","author":"GFP Aleixo","year":"2020","unstructured":"Aleixo GFP, Shachar SS, Nyrop KA et al (2020) Myosteatosis and prognosis in cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol 145:102839","journal-title":"Crit Rev Oncol Hematol"},{"key":"6190_CR105","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618781188","volume":"6","author":"G Antonelli","year":"2018","unstructured":"Antonelli\nG, Gigante E, Iavarone M, Begini P, Sangiovanni A, Iannicelli E, et al (2018) Sarcopenia is\nassociated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib\ntreatment. United European Gastroenterol J 6:1039. https:\/\/doi.org\/10.1177\/2050640618781188","journal-title":"United European Gastroenterol J"},{"key":"6190_CR2","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.afos.2021.03.002","volume":"7","author":"PC-M Au","year":"2021","unstructured":"Au PC-M, Li H-L, Lee GK-Y et al (2021) Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia 7:S28\u2013S33","journal-title":"Osteoporos Sarcopenia"},{"key":"6190_CR3","doi-asserted-by":"publisher","first-page":"1133S","DOI":"10.3945\/ajcn.2010.28608C","volume":"91","author":"VE Baracos","year":"2010","unstructured":"Baracos VE, Reiman T, Mourtzakis M et al (2010) Body composition in patients with non\u2212small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91:1133S-1137S","journal-title":"Am J Clin Nutr"},{"key":"6190_CR106","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/cancers16061080","volume":"16","author":"M Biselli","year":"2024","unstructured":"Biselli M, Reggidori N,\nIavarone M, Renzulli M, Lani L, Granito A, et al(2024) Impact of Sarcopenia on the Survival of Patients with\nHepatocellular Carcinoma Treated with Sorafenib. Cancers 16:1080.\nhttps:\/\/doi.org\/10.3390\/CANCERS16061080","journal-title":"Cancers"},{"key":"6190_CR4","first-page":"512","volume":"33","author":"CB Bin","year":"2023","unstructured":"Bin CB, Liang PC et al (2023) Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol 33:512\u2013522","journal-title":"Eur Radiol"},{"key":"6190_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1001\/jamaoncol.2018.0137","volume":"4","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798\u2013804","journal-title":"JAMA Oncol"},{"key":"6190_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/lt.24750","volume":"23","author":"EJ Carey","year":"2017","unstructured":"Carey EJ, Lai JC, Wang CW et al (2017) A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 23:625\u2013633","journal-title":"Liver Transpl"},{"key":"6190_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/jcsm.12538","volume":"11","author":"MP Chu","year":"2020","unstructured":"Chu MP, Li Y, Ghosh S et al (2020) Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J Cachexia Sarcopenia Muscle 11:748\u2013755","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6190_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/hpb.12394","volume":"17","author":"RJS Coelen","year":"2015","unstructured":"Coelen RJS, Wiggers JK, Nio CY et al (2015) Preoperative computed tomography assessment of skeletal muscle mass is valuable in predicting outcomes following hepatectomy for perihilar cholangiocarcinoma. HPB (Oxford) 17:520\u2013528","journal-title":"HPB (Oxford)"},{"key":"6190_CR100","doi-asserted-by":"publisher","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169","DOI":"10.1093\/ageing\/afy169"},{"key":"6190_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-29825-5","volume":"8","author":"BA Derstine","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE et al (2018) (2018) Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 8:1\u20138","journal-title":"Sci Rep"},{"key":"6190_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495","journal-title":"Lancet Oncol"},{"key":"6190_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2319","volume":"3","author":"EMC Feliciano","year":"2017","unstructured":"Feliciano EMC, Kroenke CH, Meyerhardt JA et al (2017) Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol 3:e172319","journal-title":"JAMA Oncol"},{"key":"6190_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1152\/jappl.2000.89.1.104","volume":"89","author":"BH Goodpaster","year":"2000","unstructured":"Goodpaster BH, Kelley DE, Thaete FL et al (2000) (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 89:104\u2013110","journal-title":"J Appl Physiol"},{"key":"6190_CR102","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.3390\/cancers16193356","volume":"16","author":"AJ L\u00e1inez Ramos-Bossini","year":"2024","unstructured":"L\u00e1inez Ramos-Bossini AJ, G\u00e1mez Mart\u00ednez A, Luengo G\u00f3mez D, Valverde-L\u00f3pez F, Melguizo C, Prados J (2024) Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cancers (Basel) 16:3356.\nhttps:\/\/doi.org\/10.3390\/CANCERS16193356\/S1","journal-title":"Cancers (Basel)"},{"key":"6190_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/10428194.2013.816421","volume":"55","author":"H Lanic","year":"2014","unstructured":"Lanic H, Kraut-Tauzia J, Modzelewski R et al (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55:817\u2013823","journal-title":"Leuk Lymphoma"},{"key":"6190_CR101","doi-asserted-by":"publisher","unstructured":"Li H-L, Au PCM, Lee GK-Y, Li GH-Y, Chan M, Cheung BM-Y, et al (2021) Different definition of sarcopenia and mortality in cancer: A meta-analysis. Osteoporos Sarcopenia 7:S34. https:\/\/doi.org\/10.1016\/J.AFOS.2021.02.005","DOI":"10.1016\/J.AFOS.2021.02.005"},{"key":"6190_CR104","doi-asserted-by":"publisher","unstructured":"Liu J, Luo H, Huang L, Wang J. Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta analysis. Oncol Lett 2023;26. https:\/\/doi.org\/10.3892\/OL.2023.13869","DOI":"10.3892\/OL.2023.13869"},{"key":"6190_CR103","doi-asserted-by":"publisher","unstructured":"March C, Omari J, Thormann M, Pech M, Wienke A, Surov A. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis. Clin Nutr ESPEN 2022;49:103\u201313. https:\/\/doi.org\/10.1016\/J.CLNESP.2022.04.009","DOI":"10.1016\/J.CLNESP.2022.04.009"},{"key":"6190_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, MacDonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539\u20131547","journal-title":"J Clin Oncol"},{"key":"6190_CR16","doi-asserted-by":"publisher","first-page":"7631","DOI":"10.1038\/s41598-023-33349-y","volume":"13","author":"I Molwitz","year":"2023","unstructured":"Molwitz I, Recklies F, Stark M et al (2023) Muscle quality determined by computed tomography predicts short-term and long-term survival after liver transplantation. Sci Rep 13:7631","journal-title":"Sci Rep"},{"key":"6190_CR17","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222008","author":"M Nachit","year":"2023","unstructured":"Nachit M, Horsmans Y, Summers RM et al (2023) AI-based CT body composition identifies myosteatosis as key mortality predictor in asymptomatic adults. Radiology. https:\/\/doi.org\/10.1148\/radiol.222008","journal-title":"Radiology"},{"key":"6190_CR18","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.2018.78.6988","volume":"36","author":"E Parkin","year":"2018","unstructured":"Parkin E, Renehan AG (2018) Need to distinguish the term sarcopenia from risk stratification derived from muscle parameters. J Clin Oncol 36:2131\u20132132","journal-title":"J Clin Oncol"},{"key":"6190_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1148\/radiol.211561","volume":"303","author":"PJ Pickhardt","year":"2022","unstructured":"Pickhardt PJ (2022) Value-added opportunistic CT screening: state of the art. Radiology 303:241\u2013254","journal-title":"Radiology"},{"key":"6190_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629\u2013635","journal-title":"Lancet Oncol"},{"key":"6190_CR22","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2015.0365","author":"H Rahemi","year":"2015","unstructured":"Rahemi H, Nigam N, Wakeling JM (2015) The effect of intramuscular fat on skeletal muscle mechanics: implications for the elderly and obese. J R Soc Interface. https:\/\/doi.org\/10.1098\/rsif.2015.0365","journal-title":"J R Soc Interface"},{"key":"6190_CR23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H et al (2019) Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 71:1164\u20131174","journal-title":"J Hepatol"},{"key":"6190_CR24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1634\/theoncologist.2016-0066","volume":"21","author":"HN Rier","year":"2016","unstructured":"Rier HN, Jager A, Sleijfer S et al (2016) The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature. Oncologist 21:1396\u20131409","journal-title":"Oncologist"},{"key":"6190_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/SLA.0000000000002679","volume":"268","author":"C Simonsen","year":"2018","unstructured":"Simonsen C, de Heer P, Bjerre ED et al (2018) Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology. Ann Surg 268:58\u201369","journal-title":"Ann Surg"},{"key":"6190_CR26","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.clnu.2016.03.010","volume":"35","author":"B Sj\u00f8blom","year":"2016","unstructured":"Sj\u00f8blom B, Gr\u00f8nberg BH, Wentzel-Larsen T et al (2016) Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr 35:1386\u20131393","journal-title":"Clin Nutr"},{"issue":"8","key":"6190_CR28","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/jpen.2415","volume":"46","author":"A Surov","year":"2022","unstructured":"Surov A, Wienke A (2022) Prevalence of sarcopenia in patients with solid tumors: a meta-analysis based on 81,814 patients. J Parent Enteral Nutr 46(8):1761\u20131768","journal-title":"J Parent Enteral Nutr"},{"key":"6190_CR29","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1016\/j.clnu.2021.08.023","volume":"40","author":"A Surov","year":"2021","unstructured":"Surov A, Pech M, Gessner D et al (2021) Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clin Nutr 40:5298\u20135310","journal-title":"Clin Nutr"},{"issue":"9","key":"6190_CR30","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1007\/s00330-023-09524-0","volume":"33","author":"A Surov","year":"2023","unstructured":"Surov A, Strobel A, Borggrefe J, Wienke A (2023a) Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis. Eur Radiol 33(9):6426\u20136437","journal-title":"Eur Radiol"},{"key":"6190_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112939","volume":"190","author":"A Surov","year":"2023","unstructured":"Surov A, Wienke A, Gutzmer R (2023b) Time to include sarcopenia into the oncological routine. Eur J Cancer 190:112939","journal-title":"Eur J Cancer"},{"key":"6190_CR107","doi-asserted-by":"publisher","unstructured":"Thormann M, Meyer HJ, Wienke A, Niehoff J, Kr\u00f6ger JR, Gutzmer R, et al (2025) The Prevalence of Sarcopenia in Patients with Solid Tumors Differs Across Regions: A Systematic Review. Nutr Cancer 77. https:\/\/doi.org\/10.1080\/01635581.2024.2401648","DOI":"10.1080\/01635581.2024.2401648"},{"key":"6190_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41430-017-0034-5","volume":"72","author":"A Van Der Werf","year":"2018","unstructured":"Van Der Werf A, Langius JAE, De Van Der Schueren MAE et al (2018) Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. Eur J Clin Nutr 72:288\u2013296","journal-title":"Eur J Clin Nutr"},{"key":"6190_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/bjs.7823","volume":"99","author":"MG Van Vledder","year":"2012","unstructured":"Van Vledder MG, Levolger S, Ayez N et al (2012) Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 99:550\u2013557","journal-title":"Br J Surg"},{"key":"6190_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/crt2.60","volume":"8","author":"JW Wang","year":"2023","unstructured":"Wang JW, Chen J, McGregor AH, Williams M (2023) A review of radiological definitions of sarcopenia in cancer. JCSM Clin Rep 8:36\u201345","journal-title":"JCSM Clin Rep"},{"key":"6190_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.05.012","volume":"71","author":"AW Wendrich","year":"2017","unstructured":"Wendrich AW, Swartz JE, Bril SI et al (2017) Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol 71:26\u201333","journal-title":"Oral Oncol"},{"key":"6190_CR36","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/jcsm.12961","volume":"13","author":"LB Westenberg","year":"2022","unstructured":"Westenberg LB, Zorgdrager M, Viddeleer AR, Pol RA (2022) Defining sarcopenia and myosteatosis: the necessity for consensus on a technical standard and standardized cut-off values. J Cachexia Sarcopenia Muscle 13:1429\u20131430","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6190_CR37","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1200\/JCO.21.00102","volume":"39","author":"GR Williams","year":"2021","unstructured":"Williams GR, Dunne RF, Giri S et al (2021) Sarcopenia in the older adult with cancer. J Clin Oncol 39:2068\u20132078","journal-title":"J Clin Oncol"},{"key":"6190_CR38","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.clnu.2023.10.006","volume":"42","author":"W Zhang","year":"2023","unstructured":"Zhang W, Tang J, Tang H et al (2023) Different computed tomography parameters for defining myosteatosis in patients with advanced non-small cell lung cancer. Clin Nutr 42:2414\u20132421","journal-title":"Clin Nutr"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06190-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06190-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T22:50:49Z","timestamp":1747090249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06190-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["6190"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06190-1","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived by the Institutional Review Board","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The scientific guarantor of this study is Alexey Surov.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"One author has significant statistical expertise (Andreas Wienke).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"No study subjects or cohorts have been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}}],"article-number":"141"}}